These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 18567870)
1. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Christadoss P; Tüzün E; Li J; Saini SS; Yang H Ann N Y Acad Sci; 2008; 1132():210-9. PubMed ID: 18567870 [TBL] [Abstract][Full Text] [Related]
2. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis. Tüzün E; Saini SS; Yang H; Alagappan D; Higgs S; Christadoss P J Neuroimmunol; 2006 May; 174(1-2):157-67. PubMed ID: 16527362 [TBL] [Abstract][Full Text] [Related]
3. Targeting classical complement pathway to treat complement mediated autoimmune diseases. Tüzün E; Li J; Saini SS; Yang H; Christadoss P Adv Exp Med Biol; 2008; 632():265-72. PubMed ID: 19025128 [TBL] [Abstract][Full Text] [Related]
4. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. Tüzün E; Scott BG; Goluszko E; Higgs S; Christadoss P J Immunol; 2003 Oct; 171(7):3847-54. PubMed ID: 14500686 [TBL] [Abstract][Full Text] [Related]
5. Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. Tüzün E; Li J; Saini SS; Yang H; Christadoss P J Neuroimmunol; 2007 Jan; 182(1-2):167-76. PubMed ID: 17137637 [TBL] [Abstract][Full Text] [Related]
6. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Tüzün E; Saini SS; Ghosh S; Rowin J; Meriggioli MN; Christadoss P Neuromuscul Disord; 2006 Feb; 16(2):137-43. PubMed ID: 16427283 [TBL] [Abstract][Full Text] [Related]
7. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells. Duan RS; Adikari SB; Huang YM; Link H; Xiao BG Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302 [TBL] [Abstract][Full Text] [Related]
8. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis. Tüzün E; Saini SS; Morgan BP; Christadoss P J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125 [TBL] [Abstract][Full Text] [Related]
10. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis. Xiao BG; Duan RS; Zhu WH; Lu CZ Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165 [TBL] [Abstract][Full Text] [Related]
11. Animal models of myasthenia gravis. Christadoss P; Poussin M; Deng C Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092 [TBL] [Abstract][Full Text] [Related]
12. Complement C2 siRNA mediated therapy of myasthenia gravis in mice. Huda R; Tüzün E; Christadoss P J Autoimmun; 2013 May; 42():94-104. PubMed ID: 23410585 [TBL] [Abstract][Full Text] [Related]
13. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis. Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409 [TBL] [Abstract][Full Text] [Related]
17. Genetic deficiency of estrogen receptor alpha fails to influence experimental autoimmune myasthenia gravis pathogenesis. Qi H; Li J; Allman W; Saini SS; Tüzün E; Wu X; Estes DM; Christadoss P J Neuroimmunol; 2011 May; 234(1-2):165-7. PubMed ID: 21481948 [TBL] [Abstract][Full Text] [Related]
18. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. Paas-Rozner M; Dayan M; Paas Y; Changeux JP; Wirguin I; Sela M; Mozes E Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2168-73. PubMed ID: 10681457 [TBL] [Abstract][Full Text] [Related]
19. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis. Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908 [TBL] [Abstract][Full Text] [Related]